TrialJournal of the American Heart Association2023

Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT.

Brian Olshansky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.